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Tissue and matrix stiffness affect cell properties during morphogenesis, cell growth, differentiation, and migration and are altered
in the tissue remodeling following injury and the pathological progression. However, detailed molecular mechanisms underlying
alterations of stiffness in vivo are still poorly understood. Recent engineering technologies have developed powerful techniques to
characterize the mechanical properties of cell and matrix at nanoscale levels. Extracellular matrix (ECM) influences mechanical
tension and activation of pathogenic signaling during the development of chronic fibrotic diseases. In this short review, we will
focus on the present knowledge of the mechanisms of how ECM stiffness is regulated during the development of liver fibrosis and
the molecules involved in ECM stiffness as a potential therapeutic target for liver fibrosis.
1. Introduction
Each tissue/organ has an optimum stiffness level. The tis-
sue/organ stiffness changes in response to biochemical and
physical stimuli during the development or due to patholog-
ical conditions such as chronic fibrotic disease and cancer
progression [1, 2].
Atomic force microscopy (AFM) allows surface topog-
raphy of tissues to be imaged with a nanometer spatial
resolution using a sharp tip attached to a cantilever. In
addition to surface imaging, AFM enables the measurement
of mechanical data from tip/sample interaction [3]. AFM is
widely used inmeasuring tissue/organ stiffness at a nanoscale
level and cell mechanics. The elastic modulus is typically
reported using such AFM data [1, 4]. A number of studies
using AFM have assessed tissue/organ stiffness and have
revealed that the elastic modulus of soft tissues such as liver,
lung, and skin is approximately one-fifth of the level ofmuscle
tissues [1, 4].
Many studies suggest that ECM stiffness affects biological
properties of cells and tissues. For example, naive mesenchy-
mal stem cells cultured on soft matrices that mimic brain
exhibit neurogenic phenotype, whereas those cultured on
stiffer matrices that mimic muscle exhibit myogenic pheno-
type, suggesting that matrix elasticity governs lineage and
phenotypes of stemcells [5].NIH3T3fibroblasts on substrates
with a rigidity gradient can generate stronger traction forces
and spread to a larger size on stiff substrates than on soft
substrates [6]. Elevatingmatrix stiffness increases cell growth
and disrupts epithelial morphogenesis by enhancing integrin
clustering, extracellular signal-regulated kinase (ERK) acti-
vation, and Rho-generated contractility [7]. A recent insight-
ful study shows that collagen cross-linking, which elevates
tissue stiffness, leads to cancer progression by enhancing
ECM receptor integrin signaling [8]. Therefore, analysis
of matrix/tissue stiffness provides us with new insights in
understanding the pathological mechanisms of tumor and
fibrotic diseases.
Collagen is the most abundant component of scaffold-
ing ECM in tissue/organ stroma [9, 10] and essential for
macromolecular structure and organizations in the ECM.
Indeed, collagen-mediated ECM networks have an effect
on biological properties such as matrix/tissue stiffness and
tissue/organ structure. Type I collagen is a member of fibril-
forming collagen and the major molecule of collagen fibrils
(more than 90%) in bone, tendon, ligament, and skin and
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also all major organs such as heart, kidney, liver, lung, and
spleen in vertebrates [10]. Type I collagen is synthesized as
procollagen and then forms fibrils after enzyme-mediated
removal of both N- and C-terminus propeptides [10]. Cova-
lent cross-linking occurs among intra- and intermolecular
chain of collagens [11], which results in the stabilization and
enhancedmechanical properties in extracellular collagen [12,
13]. We have recently discovered that there are at least two
independent mechanisms of type I collagen fibrillogenesis
in response to adult tissue/organ injury: ECM glycopro-
tein fibronectin-mediated and transforming growth factor-
(TGF-) 𝛽/type V collagen-mediated [14].
TGF-𝛽 plays a pivotal role as a profibrogenic mas-
ter cytokine in promoting differentiation of tissue-resident
fibroblasts intomyofibroblasts and upregulation of ECMpro-
duction, including fibronectin and collagen [15, 16]. TGF-𝛽 is
secreted into ECM as a biologically inactive (latent) complex
with TGF-𝛽 latency-associated protein and latent TGF-𝛽-
binding protein- (LTBP-) 1. In response to injury, latent TGF-
𝛽 is converted to an active form to bind its receptor. Indeed,
TGF-𝛽 bioavailability is increased in chronic fibrotic diseases,
whereas inhibition of latent TGF-𝛽 activation prevents the
progression of fibrosis [17–20], implying that local activation
of latent TGF-𝛽 is a critical step in the control of TGF-𝛽
activity. Importantly, local TGF-𝛽 bioavailability is negatively
regulated by fibronectin following adult tissue/organ damage
[14, 21].
Liver is responsible for themetabolism, synthesis, storage,
and redistribution of nutrients, and it has a central role
in homeostasis. Liver injury can be induced by chronic
infection with hepatotropic viruses (mainly hepatitis B and
C viruses) and autoimmune injury as well as by metabolic
and toxic/drug-induced causes, with chronic alcohol con-
sumption being predominant in western countries. Interest-
ingly, the adult liver has a very high regenerative capacity.
Adult liver can completely recover within weeks even after
70% resection of the total liver (partial hepatectomy) [22].
However, if liver injury persists, liver regeneration fails and
this results in the excessive accumulation of collagenous
ECM (mainly type I collagen, termed “liver fibrosis”). Thus,
liver fibrosis is the common outcome in all chronic liver
diseases. Liver fibrosis has great clinical importance because
it is reversible in the early stages, before disruption of the
normal liver architecture and the eventual impairment of
liver function [23]. Liver cirrhosis, the end-stage irreversible
consequence of liver fibrosis, causes significant morbidity
and mortality and is characterized by the formation of
regenerative nodules of parenchyma surrounded and sepa-
rated by fibrotic septa. 170 million patients worldwide are
affected by chronic liver disease, 25–30% of whom will
develop significant fibrosis and eventually cirrhosis. Eventu-
ally, many patients suffer from progressive liver cirrhosis and
are required to get liver transplants. Currently, there are no
biomarkers that can be used to identify patients who might
benefit from a specific therapy; also there are no biomarkers
that can reliably predict the progression to liver fibrosis and
the development of cirrhosis [24, 25].
In response to liver damage, myofibroblasts such as acti-
vated hepatic stellate cells (HSCs) play a central role in ECM
remodeling [23]. In quiescent conditions, HSCs are located
in the subendothelial space and store vitamin A droplets
[69]. Quiescent HSCs express makers that are characteristic
of adipocytes (PPAR𝛾, SREBP-1c, and leptin) [23]. Following
liver injury, HSCs, like tissue-resident fibroblasts in other
organs, transdifferentiate into proliferative myofibroblasts,
expressing high levels of myogenic markers (alpha smooth
muscle actin [𝛼-SMA], c-myb, and MEF-2) and acquiring
contractile, proinflammatory, and fibrogenic properties [23].
Activated HSCs proliferate and migrate to the sites for
tissue repair, secreting large amounts of ECM and regulating
ECM degradation [23]. Surprisingly, in advanced stages of
liver fibrosis, fibrotic livers accumulate approximately up to
6 times more ECM compared to normal livers, including
collagens, fibronectin, and laminin [23]. A recent in vitro
observation has revealed that primary rat HSCs cultured for
7 days on soft substrates appear morphologically quiescent,
whereas HSCs cultured on stiffer substrates exhibit typical
features of myofibroblast (increased spreading and 𝛼-SMA
expression), suggesting that alteration of liver matrix stiffness
drives the pathological progression of fibrosis [70]. However,
it remains to be elucidated how ECM stiffness is regulated
following liver injury and how activated HSCs contribute to
ECM stiffness during the development of liver fibrosis. In
this short review, we will focus on the present knowledge of
the regulatorymechanisms ofmatrix stiffness in chronic liver
fibrosis.
2. Molecules Regulating Extracellular
Matrix Stiffness
As described above, collagen cross-linking enhances the
ECM stiffness [11]. Accumulating observations have iden-
tified molecules regulating protein cross-linking and ECM
stiffness (Table 1). The molecules regulating ECM stiffness
have relevance to chronic diseases including tissue fibrosis,
neurodegenerative, autoimmune disease, and cancer [27, 71].
2.1. Lysyl Oxidase Family. The lysyl oxidase (LOX) family
contains at least five members: LOX-like 1 (LOXL1), LOXL2,
LOXL3, and LOXL4, in addition to LOX [12, 26]. They
belong to an amine oxidase family and copper-dependently
catalyze the posttranslational oxidation of peptidyl lysine to
the peptidyl aldehyde, 𝛼-aminoadipic-𝛿-semialdehyde [12].
This chemical modification is known to be induced by
profibrogenic cytokine TGF-𝛽, enables the covalent cross-
linking in fibrillar collagens and elastins, and thus results in
the insolubilization and stabilization of ECM proteins [8, 72].
LOX is secreted as inactive proenzyme (proLOX) and
then extracellularly cleaved to active enzyme by C-proteinase
[12, 26]. In vitro study raises the possibility that the proteolytic
activation of proLOX occurs on the cell surface in a complex
with cellular form of fibronectin [73]. LOX binds to cellular
fibronectin at higher binding affinity (Kd = 2.5 nM) as well as
type I collagen (Kd = 5.2 nM) and tropoelastin (Kd = 1.9 nM),
although it is unlikely that cellular fibronectin acts as a sub-
strate of LOX. LOX colocalizes well with cellular fibronectin
in both cultured fibroblasts in vitro and normal human tissues
in vivo. Interestingly, fibronectin-null embryonic fibroblasts
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Table 1: Extracellular matrix stiffness-regulating molecules.
Molecules Biological functions References
LOX Catalyzing cross-linking of collagen and elastin [12, 26]
LOX-like 1–4 Catalyzing cross-linking of collagen and elastin [12, 26]
Tissue transglutaminase Catalyzing cross-linking of ECM proteins [27]
Fibronectin Decreasing LOX family expression [21]
TGF-𝛽 Increasing collagen, LOX family expression [15, 26]
PDGF Increasing LOX expression [28, 29]
IL-1𝛽 Increasing LOX expression [30]
TNF-𝛼
Decreasing LOX expression (1–5 ng/mL) [31]
Increasing LOX expression (10–30 ng/mL)
Prostaglandin E Decreasing LOX expression [30]
IFN-𝛾 Decreasing LOX expression [32]
ECM, extracellular matrix; IFN-𝛾, interferon-𝛾; IL-1𝛽, interleukin-1𝛽; LOX, lysyl oxidase; MMP, matrix metalloproteinase; PDGF, platelet-derived growth
factor; TGF-𝛽, transforming growth factor-𝛽; TNF-𝛼, tumor necrosis factor-𝛼.
show significant reduction of the proteolytic processing of
proLOX [73].These findings strongly suggest that fibronectin
matrix regulates ECM stiffness via LOX activation.
LOX knockout mouse shows perinatal death caused
by developmental abnormalities in various tissues such as
diaphragm, heart, lung, skin, and vascular tissues [74–76],
demonstrating that LOX is essential for normal embryonic
development. In both human fibrotic diseases and animal
models, elevated expression and activity of LOX familymem-
bers are often observed [35, 77]. Significantly increased LOX
activity is observed in sera of patients with hepatic diseases
such as chronic hepatitis, fibrosis, and cirrhosis [78, 79],
implying the potential of LOX family as a biomarker for liver
fibrosis. LOX inhibitor 𝛽-aminopropionitrile (BAPN: small
molecule) decreases TGF-𝛽1-induced collagen fibril stiffness
in vitro and also organ stiffness following injury [21, 80].
The treatment of BAPN with mice in carbon tetrachloride-
(CCl4-) induced liver fibrosis facilitates fibrosis reversal after
CCl4 withdrawal, supporting the concept of pharmacologic
targeting of LOX pathway to inhibit liver fibrosis and pro-
mote its resolution [34]. LOXL2-specific inhibitory antibody
reduces the extent of collagen cross-linking mediated by
pSmad2/3 signaling (canonical TGF-𝛽1 signaling) in mouse
models of chemically induced fibrosis in the liver and lung
[35] and indeed anti-LOXL2 antibody (GS-6624) in the
process of clinical trials [81].
2.2. Transglutaminase Family. The transglutaminase- (TG-)
mediated, covalent cross-linking of proteins is an essential
step in tissue remodeling after injury. This process provides
tissues with extra rigidity and resistance against proteolytic
degradation. TGs are widely distributed calcium-dependent
enzymes and catalyze covalent cross-linking between 𝛾-
carboxy-amine group of a glutamine residue and the 𝜀-amino
group of a lysine residue, resulting in a 𝜀-(𝛾-glutamyl)lysine
isopeptide bond [27]. Several studies indicate the involve-
ment of TGs in human diseases such as neurodegenerative
disorders, autoimmune diseases, cancer, and tissue/organ
fibrosis [27]. The nine members of this family have been
identified: TG1 (keratinocyte TG), TG2 (tissue TG), TG3
(epidermal TG), TG4 (prostate TG), TG5 (TGX), TG6
(TGY), TG7 (TGZ), factor XIII, and band 4.2 [82].
TG2 (tissue TG) is the most abundantly expressed mem-
ber of the TGs [82]. Unlike other members, TG2 is a mul-
tifunctional protein and numerous substrates of TG2 have
been identified [27, 82]. Many ECM glycoproteins (collagen,
fibronectin, fibrinogen, vitronectin, laminin, and LTBP-1) are
known to be the substrates of TG2. An in vitro study using
Swiss 3T3 fibroblasts suggests the contribution of TG2 to
the deposition of latent TGF-𝛽 complex into ECM: LTBP-1
is codistributed with extracellular TG2 and fibronectin, and
increased TG2 expression elevates the deposition of LTBP-
1 in the matrix along with the increase of deoxycholate-
insoluble fibronectin, whereas the competitive amine sub-
strate reduces the LTBP-1 deposition in the matrix [83].
Recent studies reveal that TG2 has not only enzymatic (cross-
linking of ECM proteins) but also nonenzymatic functions
[71]. The cell surface TG2 noncovalently associates with
soluble fibronectin and integrin (𝛽1, 𝛽3, and 𝛽5), resulting
in promoting fibronectin deposition into ECM and forming
stable ternary complexes with both fibronectin and integrins
[71]. The association of TG2 with integrins potentially trig-
gers outside-in signaling. Cell surface TG2 increases RhoA
activity by integrin clustering and downregulation of Src-
p190RhoGAP inhibitory pathway, enhancing formation of
focal adhesion and actin stress fibers [71, 84]. It is therefore
likely that TG2 affects ECM/tissue properties via regulating
ECM cross-linking and cell-ECM interactions.
Upregulation of TGmRNA and protein levels is observed
in human and murine liver fibrosis progression [36, 85].
However, TG2-knockout mice show a comparable extent and
pattern of liver fibrosis compared to wild-type controls in
CCl4- and thioacetamide-induced chronic liver injury [36].
Furthermore, reversal after CCl4-induced liver fibrosis is
not accelerated in TG2-knockout mice. It is therefore likely
that TG2 does not have a major contribution to hepatic
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fibrogenesis or stabilization of the collagen matrix and that
TG2-independent collagen cross-linking (e.g., LOX family)
could be represented as an important therapeutic target for
liver fibrosis [36].
Factor XIII (FXIII) plays a central role in forming a
stable fibrin meshwork by cross-linking of fibrin during
blood clotting [86]. A number of studies have revealed
that ECM proteins such as fibronectin, collagen (type I, II,
III, and V), and vitronectin are also substrates of FXIII.
For example, fibronectin is cross-linked to fibrin 𝛼 chain
by FXIII and this cross-linking produces denser clots [86].
Although fibronectin does not affect clot rigidity at physio-
logical concentrations [86], fibronectin-fibrin cross-linking is
required for fibroblast adhesion and spreading onfibronectin.
However, the molecular mechanisms underlying impaired
wound healing in patients lacking FXIII are still largely
unknown [87, 88]. Moreover, the functional requirement
for FXIII-mediated cross-linked provisional matrix between
fibrin and fibronectin in adult tissue remodeling remains
to be defined. We have demonstrated in an FXIII subunit
A deficient murine model of acute liver injury that the
lack of FXIII subunit A does not interfere with collagen
reconstruction and resolution after liver injury. Furthermore,
FXIIIA deficiency has caused significantly increased hepato-
cyte apoptosis and a delay in hepatocyte regeneration after
injury, which are accompanied by a high induction of p53
expression. These findings strongly suggest a novel function
of FXIII where the FXIII-mediated covalently cross-linked
matrix could promote survival signals for hepatocytes in
adult tissue remodeling [33].
2.3. A Disintegrin and Metalloproteinase with Thrombospon-
din Type I Motif 2 (ADAMTS2). ADAMTS (a disinte-
grin and metalloproteinase with thrombospondin motif)
enzymes are extracellular proteases and belong to themetzin-
cin protease superfamily [89]. They are subgrouped on the
basis of their substrates: the aggrecanases or proteoglycan-
ases (ADAMTS1, ADAMTS4, ADAMTS5, ADAMTS8,
ADAMTS9, ADAMTS15, and ADAMTS20), the procollagen
N-propeptidases (ADAMTS2,ADAMTS3, andADAMTS14),
the cartilage oligomeric matrix protein-cleaving enzymes
(ADAMTS7 and ADAMTS12), the von Willebrand factor
proteinase (ADAMTS13), and a group of orphan enzymes
(ADAMTS6, ADAMTS10, ADAMTS16, ADAMTS17,
ADAMTS18, and ADAMTS19) [89]. A very recent in vitro
study shows that ADMTS2, ADAMTS3, and ADAMTS14
cleave LTBP-1 and TGF-𝛽 RIII (𝛽-glycan) and that
ADAMTS2 silencing inhibits TGF-𝛽1- or TGF-𝛽2-induced
expression of connective tissue growth factor and 𝛼-SMA in
human dermal fibroblasts [90]. ADAMTS2-deficient mice
show reduced hepatic fibrosis in chronic liver injury induced
by CCl4, whereas a single CCl4 injection causes a similar
acute liver injury in knockout and wild-type mice [37].
These findings suggest that ADAMTS2 promotes fibrosis via
activation of TGF-𝛽 signaling and that ADAMTS2 might
be a novel therapeutic target for liver fibrosis. However, it is
unclear whether ADAMTS2 level is elevated in patients with
liver fibrosis and whether ADAMTS inhibitors ameliorate
fibrosis progression and/or accelerate the regression in
animal models. Further studies remain to be elucidated to
clarify the contribution of ADAMTS to ECM stiffening and
progression/regression of liver fibrosis.
2.4. Small Leucine-Rich Proteoglycans/Protein Family. Small
leucine-rich proteoglycans/protein (SLRP) family consists of
five classes (I–V) and the canonical class is classes I, II, and, III
including decorin, biglycan, lumican, and fibromodulin [91].
Almost all SLRPs bind collagen fibrils through their leucine-
rich repeat domain. Lines of evidence show that SLRPs
contribute significantly to the diameter and/or alter structure
of collagen fibrils [91–93]. A dynamic modulus in biglycan-
null tendons is significantly increased compared to wild-type
tendons [94]. The elasticity of collagen fiber networks in
cultured decorin-siRNA-transfected mouse NIH3T3 fibrob-
lasts declines during the incubation period, whereas it is
unchanged in untransfected cells [95]. It is therefore likely
that SLRPs could regulate the mechanical strength of ECM.
3. Characterization of Liver Mechanics
In Vitro and In Vivo
The role of mechanical factors in myofibroblastic activation
and fibrosis has been recognized for many years [80, 96].
Hence, appropriate techniques are needed to accurately
characterize the mechanical changes associated with liver
fibrosis. Studies on liver mechanics have been limited due
to numerous factors including small sample sizes, variable
methodologies, and tissue storage methods. However, it is
widely reported that liver is a viscoelastic tissue and that stiff-
ness increases with increasing fibrosis. A range of techniques
have been applied to characterize livermechanics both in vivo
and in vitro. For example, magnetic resonance elastography
(MRE) has long been used for noninvasive assessment of
liver fibrosis [97] and new developments ofMRE allow three-
dimensional spin-echo echo planar imaging [98].
For in vitro analysis, oscillatory rheometry which pro-
vides the complex shear modulus of liver tissue is typically
used for characterization of liver stiffness and data obtained
with this technique has been found to correlate with in vivo
MREmeasurements [99]. Mechanical tissue characterization
with rheometry involves the analysis of the complex shear
modulus. Very recently, it is shown that the shear storage (G󸀠),
loss (G󸀠󸀠), and apparent Young’s moduli increase markedly
with progressive fibrosis in rat livers [100]. They suggest
that both cells and the ECM contribute significantly to the
mechanical properties of the tissue and that these are driven
by cell-cell and cell-ECM contacts. Whilst such approaches
provide fundamental mechanical property information on
biopsy samples of liver and can be used to develop a consti-
tutive model to understand behavior [100], the information
yielded for the samples is at the macroscopic/gross level.
Similar to other soft tissues, in the liver, the key components
of the ECM, which are altered with fibrosis, are organized at
length scales which are not discriminated with conventional
mechanical testing techniques [3]. Techniques such as AFM
allow themechanical properties to be probed at the nanoscale
and hence open up exciting new areas of research into
how the specific components of the tissue microstructure
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influence its mechanical behavior [3]. AFM was originally
developed as a topographic imaging technique but is a highly
versatile technique where the contrast in AFM images is
related to the tip/sample interaction and hence the elastic
properties of both tip and substrate [3]. For mechanical
property measurements, AFM is typically used in force
spectroscopy mode where the mechanical properties of a
sample are determined with a high resolution but without
correlated surface topography. A recent review byMaver et al.
provides an overview of various AFM modes and its use for
biomedical applications [101]. The challenges and limitations
of AFM-based quantitative mechanical analysis have been
reviewed elsewhere [3].
AFM has been used widely to study cell elasticity [102,
103] but to date there are few studies which have determined
changes in the properties of native liver tissue with AFM.
Recent applications of AFM methods to tissue highlight the
utility of such AFM experiments. Zhao et al. [104] used
AFM to determine the elastic modulus of biopsy samples
obtained from a large cohort of patients in an investigation on
the relationship between matrix stiffness and hepatocellular
carcinoma. They found a positive correlation between ECM
mechanical stiffness and integrin 𝛽1 expression, suggesting
that integrin 𝛽1 expression is regulated by the mechanical
stiffness of the ECM. Desai et al. have conducted a detailed
AFM study on mice liver lobules from normal and fibrotic
livers. They demonstrated that normal liver matrix stiff-
ness was around 150 Pa but increased to 1–6 kPa in areas
near fibrillar collagen deposition in fibrotic livers [105].
We have investigated whether ECM glycoprotein fibronectin
could be a suitable target for ameliorating fibrosis during
advanced stages of chronic liver injury, particularly focusing
on themolecularmechanisms responsible formatrix stiffness
[21]. We have discovered in liver fibrogenesis induced by
CCl4 that fibronectin-null livers have exhibited constitutively
elevated local TGF-𝛽 activity and lysyl oxidase expres-
sions, induced more myofibroblast phenotypes, accumulated
highly disorganized/diffuse collagenous ECM networks, and
consequently have led to more extensive liver cirrhosis.
Importantly, these phenotypes in fibronectin-null livers are
accompanied by significantly elevated liver matrix stiffness,
as determined by AFM, and deteriorated hepatic functions.
The novel aspect of our AFM experiments is that we have
simultaneously imaged the ultrastructure of the tissue and
colocated the mechanical properties, using a novel AFM
mechanical mapping method [106]. We have found that
there is approximately a 55% increase in the elastic mod-
ulus of fibronectin-null livers compared to controls in vivo
(5,128 ± 553.6MPa in mutant versus 3,313 ± 835.2MPa in
control (𝑛 = 9); 𝑃 < 0.05; measured at ambient con-
ditions) [21]. Further in vitro mechanical integrity analysis
reveals that TGF-𝛽1- (2 pM-) induced collagen fibril stiffness
in fibronectin-null hepatic myofibroblasts (activated HSCs)
is found to be significantly higher compared to control
(parental) cells. Furthermore, the treatment of fibronectin-
null HSCs with 10 𝜇g/mL plasma fibronectin has recovered
collagen fibril stiffness to parental cell levels in vitro [21].
Thus, taken together, these findings indicate that elevated
TGF-𝛽 bioavailability in fibronectin-null livers induces more
activemyofibroblasts and sustains their activated phenotypes.
As a consequence, these myofibroblasts develop more accu-
mulated collagenous ECMs during advanced chronic liver
damage, which thereby results in the significant deterioration
of net hepatic function. We propose that there are func-
tional links between fibronectin-mediated control of TGF-𝛽
bioavailability and collagen fibril stiffness.
4. Perspectives
Fibrosis is characterized by ECM remodeling and stiffening.
Accumulating studies using animal models suggest that the
molecules involved in ECM remodeling and stiffening have
potential as a therapeutic target for liver fibrosis (Table 2)
[107]. Several antifibrotic drugs for fibrosis, including liver
fibrosis, are in the process of clinical trials [23, 81, 108].
To date, the therapeutic concept for liver fibrosis has been
etiology-driven to ameliorate and eliminate the causative
agents of chronic liver disease [81]. More recently, the
biochemical changes affecting liver fibrosis irreversibility
have become the focus, that is, direct approaches targeting
specific ECMs and the extent ofmatrix stiffness cross-linking.
For example, intravenous injection of nanoparticle loaded
with procollagen 𝛼1(I) siRNA ameliorates progression and
accelerates regression of hepatic fibrosis in mice without
detectable side effects [44], suggesting that inhibition of de
novo collagen synthesis could be a concept in the devel-
opment of therapeutic agents for chronic hepatic fibrosis.
Tissue-resident fibroblasts transdifferentiate into myofibrob-
lasts in response to injury and are responsible for ECM
production and remodeling. There are at least two inde-
pendent mechanisms in type I collagen network organiza-
tion (fibronectin- and TGF-𝛽/type V collagen-mediated) in
response to adult tissue/organ damage [14]. It remains to
be elucidated how each mechanism contributes to matrix
stiffness during the development of tissue/organ fibrosis.
It also remains an unsolved question how ECM stiffness
changes during the resolution of liver fibrosis and whether
ECM stiffness affects the resolution process. Recent growing
evidence has showed that activated HSCs are reverted to
quiescent-like state both in vitro [109–111] and in vivo [112,
113], raising the possibility that lowering matrix stiffness
initiates the resolution of liver fibrosis. The treatment of
LOX inhibitor BAPN decreases collagen stability during
liver fibrosis progression and facilitates fibrosis reversal after
CCl4-induced advanced liver fibrosis [34]. The monoclonal
antibody to LOXL2 has already been in the process of clinical
trials [81]. These findings suggest that the decrease of matrix
stiffness could also be a treatment strategy for hepatic fibrosis
regression.
As described in this review, each of the recent studies
suggests that AFM could be a powerful characterization
tool to understand mechanistic changes associated with liver
disease. Thus, interest in such nanoscale measurements of
livermatrix stiffness during the development and progression
of liver fibrosis are likely to increase in future work, particu-
larly with the development of new imaging modalities and
AFM hardware that improve the quality of data obtained for
biological tissues.
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Table 2: Molecular targets for hepatic injury/fibrosis in animal models.
Targets Models Agents to induceinjury/fibrosis Administrated drug
Effects on
injury/fibrosis References
Cross-linking factors
Factor XIII subunit A Knockout mouse CCl4 No effect [33]
LOX Wild-type mouse CCl4
Small molecule
inhibitor (BAPN) Decreasing [34]
LOX-like 2 Wild-type mouse CCl4 Specific antibody Decreasing [35]
Tissue transglutaminase Knockout mouse CCl4 No effect [36]
Proteases
ADAMTS2 Knockout mouse CCl4 Decreasing [37]
MMP-12 Knockout mouse Bile duct ligation Decreasing [38]
MMP-13 Knockout mouse Bile duct ligation Decreasing [39]
Osteopontin Knockout mouse CCl4 No effect [40]
Overexpression
mouse CCl4 Increasing [40]
Tissue-type plasminogen activator Knockout mouse CCl4 Increasing [41]
ECM component
Fibronectin Wild-type mouse CCl4, DMN Peptide Decreasing [42]
Knockout mouse CCl4 Increasing [21]
Periostin Knockout mouse CCl4 Decreasing [43]
Procollagen 𝛼1(I) Wild-type mouse CCl4 siRNA Decreasing [44]
Thrombospondin-1 Knockout mouse Resection Decreasing [45]
Cytokines/their receptors
Angiotensin II type 1A receptor Knockout mouse CCl4 Decreasing [46]
Angiotensin II type 2 Knockout mouse CCl4 Increasing [47]
Endothelin-A Wild-type rat Bile duct occlusion Small moleculeantagonist (LU135252) Decreasing [48]
TGF-𝛽
Wild-type rat Bile duct ligation Soluble TGF-𝛽receptor type II Decreasing [49]
Wild-type rat CCl4 BMP-7 Decreasing [50]
Wild-type mouse CCl4 BMP-7 Decreasing [50]
TGF-𝛽 type II receptor Knockout mouse CCl4 Decreasing [51]
Signal transduction/transcription
factors
FXR Wild-type rat Porcine serum, bileduct ligation
Small molecule
agonist (6-ECDCA) Decreasing [52]
JNK1 Knockout mouse CCl4, bile ductligation Decreasing [53]
MRTF-A Knockout mouse CCl4 Decreasing [54]
PPAR𝛼 Wild-type mouse
Methionine
choline-deficient
diet, thioacetamide
Endogenous ligand
(oleoylethanolamide) Decreasing [55]
PPAR𝛾
Wild-type rat CCl4
Small molecule
agonist (pioglitazone) Decreasing [56]
Wild-type mouse CCl4
Small molecule
agonist (pioglitazone) No effect [57]
Knockout mouse CCl4 Increasing [58]
Smad3 Wild-type mouse CCl4 Thyroid hormone Decreasing [59]
Knockout mouse Dimethylnitrosamine Decreasing [60]
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Table 2: Continued.
Targets Models Agents to induceinjury/fibrosis Administrated drug
Effects on
injury/fibrosis References
Others
Cannabinoid receptor CB1 Wild-type mouse CCl4
Small molecule
antagonist
(SR141716A)
Decreasing [61]
Knockout mouse CCl4, thioacetamide,bile duct ligation Decreasing [61]
Cannabinoid receptor CB2 Knockout mouse CCl4 Increasing [62]
Integrin 𝛼v𝛽6
Wild-type rat Bile duct ligation
Small molecule
antagonist
(EMD527040)
Decreasing [63]
Wild-type mouse Bile duct ligation Antibody Decreasing [64]
Knockout mouse Bile duct ligation Decreasing [64]
Interleukin-17 receptor Knockout mouse CCl4 Decreasing [65]
NOX1 Wild-type mouse CCl4
Small molecule
inhibitor
(GKT137831)
Decreasing [66]
Knockout mouse CCl4 Decreasing [67]
NOX4 Wild-type mouse CCl4
Small molecule
inhibitor
(GKT137831)
Decreasing [66]
Knockout mouse CCl4 Decreasing [67]
Plasminogen activator inhibitor Knockout mouse Bile duct ligation Decreasing [68]
6-ECDCA, 6-𝛼-ethyl-chenodeoxycholic acid; ADAMTS2, A disintegrin and metalloproteinase with thrombospondin type I motif 2; BAPN, 𝛽-
aminopropionitrile; BMP-1, bone morphogenic protein-1; CCl4, carbon tetrachloride; DDC, 3,5-diethoxycarbonyl-1,4-dihydrocollidine; DMN, dimethylni-
trosamine; FXR, farnesoid X-activated receptor; LOX, lysyl oxidase;MMP,matrixmetalloproteinase; MRTF-A,myocardin related transcription factor A; NOX,
nicotinamide adenine dinucleotide phosphate oxidase; PPAR, peroxisome proliferator-activated receptor; TGF-𝛽, transforming growth factor-𝛽.
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